Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.61
JNJ's Cash to Debt is ranked higher than
65% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. JNJ: 1.61 )
JNJ' s 10-Year Cash to Debt Range
Min: 0.21   Max: 6.01
Current: 1.61

0.21
6.01
Equity to Asset 0.56
JNJ's Equity to Asset is ranked higher than
62% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. JNJ: 0.56 )
JNJ' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.66
Current: 0.56

0.46
0.66
Interest Coverage 38.13
JNJ's Interest Coverage is ranked higher than
62% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 90.51 vs. JNJ: 38.13 )
JNJ' s 10-Year Interest Coverage Range
Min: 19.77   Max: 230.91
Current: 38.13

19.77
230.91
F-Score: 6
Z-Score: 4.94
M-Score: -2.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 25.77
JNJ's Operating margin (%) is ranked higher than
93% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. JNJ: 25.77 )
JNJ' s 10-Year Operating margin (%) Range
Min: 17.84   Max: 26.92
Current: 25.77

17.84
26.92
Net-margin (%) 19.40
JNJ's Net-margin (%) is ranked higher than
91% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. JNJ: 19.40 )
JNJ' s 10-Year Net-margin (%) Range
Min: 12.52   Max: 21.65
Current: 19.4

12.52
21.65
ROE (%) 18.68
JNJ's ROE (%) is ranked higher than
93% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. JNJ: 18.68 )
JNJ' s 10-Year ROE (%) Range
Min: 16.74   Max: 30.46
Current: 18.68

16.74
30.46
ROA (%) 10.42
JNJ's ROA (%) is ranked higher than
93% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. JNJ: 10.42 )
JNJ' s 10-Year ROA (%) Range
Min: 8.51   Max: 17.09
Current: 10.42

8.51
17.09
ROC (Joel Greenblatt) (%) 79.60
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. JNJ: 79.60 )
JNJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 37   Max: 109.92
Current: 79.6

37
109.92
Revenue Growth (%) 3.90
JNJ's Revenue Growth (%) is ranked higher than
65% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. JNJ: 3.90 )
JNJ' s 10-Year Revenue Growth (%) Range
Min: 1.4   Max: 14.8
Current: 3.9

1.4
14.8
EBITDA Growth (%) -1.50
JNJ's EBITDA Growth (%) is ranked higher than
66% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. JNJ: -1.50 )
JNJ' s 10-Year EBITDA Growth (%) Range
Min: -6.6   Max: 16.5
Current: -1.5

-6.6
16.5
EPS Growth (%) 0.20
JNJ's EPS Growth (%) is ranked higher than
70% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. JNJ: 0.20 )
JNJ' s 10-Year EPS Growth (%) Range
Min: -8.6   Max: 20.2
Current: 0.2

-8.6
20.2
» JNJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

JNJ Guru Trades in Q2 2013

Paul Tudor Jones 2,400 sh (New)
Stanley Druckenmiller 129,000 sh (New)
John Hussman 252,650 sh (+9433.96%)
Steven Cohen 21,231 sh (+375.39%)
Mark Hillman 31,147 sh (+33.57%)
James Barrow 17,156,379 sh (+4.11%)
Richard Pzena 10,401 sh (+3.24%)
PRIMECAP Management 13,996,087 sh (+2.56%)
Robert Olstein 90,000 sh (+2.27%)
Jean-Marie Eveillard 1,576,560 sh (+2.24%)
Ken Fisher 10,161,336 sh (+0.27%)
Donald Yacktman 9,760,443 sh (+0.2%)
Yacktman Focused Fund 3,800,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Meridian Funds 7,885 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
George Soros 2,534,022 sh (unchged)
Richard Snow 3,230 sh (unchged)
Jeff Auxier 97,577 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Richard Perry 388,897 sh (unchged)
Ray Dalio Sold Out
Caxton Associates Sold Out
Joel Greenblatt Sold Out
Tom Russo Sold Out
Tweedy Browne 4,339,144 sh (-0.37%)
Prem Watsa 5,915,800 sh (-0.43%)
Murray Stahl 30,802 sh (-0.48%)
Bill Frels 1,833,654 sh (-0.58%)
Sarah Ketterer 293,350 sh (-0.74%)
Dodge & Cox 38,725 sh (-1.02%)
Tom Gayner 582,950 sh (-1.67%)
Ruane Cunniff 14,307 sh (-3.1%)
Jeremy Grantham 23,171,691 sh (-3.28%)
John Rogers 95,387 sh (-4.35%)
Pioneer Investments 4,241,507 sh (-6.42%)
First Pacific Advisors 1,823,100 sh (-6.58%)
Steven Romick 1,735,000 sh (-7.22%)
Mario Gabelli 406,104 sh (-12.41%)
Chuck Royce 40,200 sh (-12.42%)
Manning & Napier Advisors, Inc 4,465,276 sh (-13.68%)
HOTCHKIS & WILEY 4,274,708 sh (-14.51%)
Michael Price 35,000 sh (-22.22%)
Vanguard Health Care Fund 3,271,100 sh (-23.36%)
Chris Davis 208,287 sh (-27.59%)
Jim Simons 727,400 sh (-55.68%)
» More
Q3 2013

JNJ Guru Trades in Q3 2013

Joel Greenblatt 32,599 sh (New)
Ray Dalio 27,293 sh (New)
Louis Moore Bacon 5,694 sh (New)
Richard Pzena 847,758 sh (+8050.74%)
Steven Cohen 151,123 sh (+611.8%)
Ruane Cunniff 74,495 sh (+420.69%)
Jim Simons 3,275,300 sh (+350.27%)
Paul Tudor Jones 7,100 sh (+195.83%)
Sarah Ketterer 426,250 sh (+45.3%)
John Rogers 127,576 sh (+33.75%)
Robert Olstein 92,000 sh (+2.22%)
Murray Stahl 31,214 sh (+1.34%)
Jean-Marie Eveillard 1,596,580 sh (+1.27%)
Mario Gabelli 409,421 sh (+0.82%)
James Barrow 17,194,257 sh (+0.22%)
Richard Snow 3,235 sh (+0.15%)
Brian Rogers 4,633,000 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Dodge & Cox 38,725 sh (unchged)
Richard Perry 388,897 sh (unchged)
Yacktman Focused Fund 3,800,000 sh (unchged)
Jeff Auxier 97,577 sh (unchged)
Stanley Druckenmiller 129,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Michael Price 35,000 sh (unchged)
Ken Fisher 10,143,775 sh (-0.17%)
Tweedy Browne 4,324,131 sh (-0.35%)
Tom Gayner 580,800 sh (-0.37%)
Bill Frels 1,815,415 sh (-0.99%)
Mark Hillman 30,829 sh (-1.02%)
PRIMECAP Management 13,813,887 sh (-1.3%)
Donald Yacktman 9,619,720 sh (-1.44%)
HOTCHKIS & WILEY 4,134,878 sh (-3.27%)
Manning & Napier Advisors, Inc 4,152,996 sh (-6.99%)
Jeremy Grantham 21,210,245 sh (-8.46%)
Pioneer Investments 3,879,715 sh (-8.53%)
Vanguard Health Care Fund 2,897,600 sh (-11.42%)
First Pacific Advisors 1,498,300 sh (-17.82%)
Steven Romick 1,425,000 sh (-17.87%)
John Hussman 202,650 sh (-19.79%)
Chris Davis 163,492 sh (-21.51%)
George Soros 1,267,000 sh (-50%)
Prem Watsa 2,941,741 sh (-50.27%)
Chuck Royce 13,500 sh (-66.42%)
» More
Q4 2013

JNJ Guru Trades in Q4 2013

Ray Dalio 113,193 sh (+314.73%)
Paul Tudor Jones 26,088 sh (+267.44%)
John Rogers 349,157 sh (+173.69%)
Stanley Druckenmiller 235,000 sh (+82.17%)
Jim Simons 5,498,400 sh (+67.87%)
Steven Cohen 224,813 sh (+48.76%)
Sarah Ketterer 559,450 sh (+31.25%)
Murray Stahl 32,614 sh (+4.49%)
Pioneer Investments 4,013,743 sh (+3.45%)
Richard Pzena 866,458 sh (+2.21%)
James Barrow 17,330,009 sh (+0.79%)
Chris Davis 164,755 sh (+0.77%)
Jean-Marie Eveillard 1,607,280 sh (+0.67%)
Mario Gabelli 411,797 sh (+0.58%)
Bill Frels 1,821,701 sh (+0.35%)
First Pacific Advisors 1,501,800 sh (+0.23%)
Ken Fisher 10,165,567 sh (+0.21%)
Michael Price 35,000 sh (unchged)
Richard Snow 3,235 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Focused Fund 3,800,000 sh (unchged)
Steven Romick 1,425,000 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Vanguard Health Care Fund Sold Out
George Soros Sold Out
Joel Greenblatt Sold Out
Louis Moore Bacon Sold Out
Tom Gayner 580,600 sh (-0.03%)
Donald Yacktman 9,610,642 sh (-0.09%)
Jeff Auxier 97,452 sh (-0.13%)
Dodge & Cox 38,625 sh (-0.26%)
Mark Hillman 30,746 sh (-0.27%)
Tweedy Browne 4,305,931 sh (-0.42%)
Manning & Napier Advisors, Inc 4,132,692 sh (-0.49%)
Ruane Cunniff 74,094 sh (-0.54%)
PRIMECAP Management 13,689,047 sh (-0.9%)
Robert Olstein 91,000 sh (-1.09%)
Jeremy Grantham 19,775,624 sh (-6.76%)
HOTCHKIS & WILEY 3,819,961 sh (-7.62%)
Richard Perry 342,277 sh (-11.99%)
Chuck Royce 11,300 sh (-16.3%)
John Hussman 102,650 sh (-49.35%)
Prem Watsa 84,700 sh (-97.12%)
» More
Q1 2014

JNJ Guru Trades in Q1 2014

Steven Romick 1,835,000 sh (+28.77%)
Brian Rogers 4,633,000 sh (unchged)
Yacktman Focused Fund 3,800,000 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Prem Watsa 2013-12-31 Reduce -97.12%15.54%$85.61 - $95.63 $ 98.967%84700
George Soros 2013-12-31 Sold Out 1.2%$85.61 - $95.63 $ 98.967%0
Vanguard Health Care Fund 2013-12-31 Sold Out 0.85%$85.61 - $95.63 $ 98.967%0
John Hussman 2013-12-31 Reduce -49.35%0.48%$85.61 - $95.63 $ 98.967%102650
Joel Greenblatt 2013-12-31 Sold Out 0.09%$85.61 - $95.63 $ 98.967%0
Ray Dalio 2013-12-31 Add 314.73%0.06%$85.61 - $95.63 $ 98.967%113193
Prem Watsa 2013-09-30 Reduce -50.27%10.26%$86.17 - $94.39 $ 98.9610%2941741
George Soros 2013-09-30 Reduce -50%1.2%$86.17 - $94.39 $ 98.9610%1267000
John Hussman 2013-09-30 Reduce -19.79%0.2%$86.17 - $94.39 $ 98.9610%202650
Vanguard Health Care Fund 2013-09-30 Reduce -11.42%0.11%$86.17 - $94.39 $ 98.9610%2897600
Joel Greenblatt 2013-09-30 New Buy0.09%$86.17 - $94.39 $ 98.9610%32599
Ruane Cunniff 2013-09-30 Add 420.69%0.03%$86.17 - $94.39 $ 98.9610%74495
Ray Dalio 2013-09-30 New Buy0.02%$86.17 - $94.39 $ 98.9610%27293
John Hussman 2013-06-30 Add 9433.96%0.98%$81.11 - $88.59 $ 98.9617%252650
Vanguard Health Care Fund 2013-06-30 Reduce -23.36%0.33%$81.11 - $88.59 $ 98.9617%3271100
Michael Price 2013-06-30 Reduce -22.22%0.11%$81.11 - $88.59 $ 98.9617%35000
Ray Dalio 2013-06-30 Sold Out 0.06%$81.11 - $88.59 $ 98.9617%0
Joel Greenblatt 2013-06-30 Sold Out 0.04%$81.11 - $88.59 $ 98.9617%0
John Hussman 2013-03-31 Reduce -99.47%0.93%$70.1 - $81.53 $ 98.9631%2650
Yacktman Focused Fund 2013-03-31 Add 22.58%0.78%$70.1 - $81.53 $ 98.9631%3800000
Donald Yacktman 2013-03-31 Add 16.02%0.57%$70.1 - $81.53 $ 98.9631%9740875
Yacktman Fund 2013-03-31 Add 15.71%0.53%$70.1 - $81.53 $ 98.9631%4050000
Ray Dalio 2013-03-31 Reduce -55.3%0.07%$70.1 - $81.53 $ 98.9631%76293
Joel Greenblatt 2013-03-31 Reduce -58.46%0.05%$70.1 - $81.53 $ 98.9631%8669
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Johnson & Johnson

John Rogers' Ariel Fund Comments on Johnson & Johnson - Feb 28, 2014

Johnson & Johnson (JNJ) was a true favorite in the 1990s mega-cap bull market, with its glory days persisting until the end of 2002. From that point through 2010, it hit a relative rough patch. During the 1991 to 2002 period, Johnson & Johnson's revenues gained a remarkable +10.2% annually; in the subsequent period they slipped to a still-solid +6.8%. Its earnings decline was not as steep. The company compounded earnings per share (EPS) at a remarkable +13.6% in the 1990s and early 2000s period before slipping to +10.4% annually in the second era. Its price/earnings (P/E) ratios showcased its increasing popularity in the first period, as well as its fall from grace. Johnson & Johnson's earnings multiple soared from 26.1x in 1991 to a lofty 37.6x in 1998 before drifting down in the bear market to 24.9x at the end of 2002. From there it plummeted, however, to a low of just 12.9x at the end of 2010. Note that while investors chopped its P/E multiple in half from 2002 to 2010, its earnings per share more than doubled...

After its slide in the current century, Johnson & Johnson took the opportunity to reinvigorate itself. Alex Gorsky, who became CEO in 2012, led a major transformation; he charged his new operations head, Sandra Peterson, with structural improvements across the company. On the pharmaceutical side, it refocused its Research & Development (R&D) on blockbuster segments such as anti-coagulants and oncology. In its medical technology division, the company boldly exited the underperforming drug-eluding stent business and deployed foreign cash through the acquisition of high-margin specialty implant maker Synthes, a Swiss company. Johnson & Johnson even bolstered its consumer brands such as Neutrogena and Band-Aid, which offer lower margins but steady cash flows. More importantly, it has gotten past the embarrassing 2010 recalls of the children's versions of Tylenol, Motrin, Zyrtec and Benadryl, and all four are now back on the shelves. We always look forward, even when analyzing a 127-year old company, and at this point see a lean, mean heavyweight ready to compete.

From John Rogers (Trades, Portfolio)' Ariel International Fund & Ariel Global Fund fourth quarter 2013 commentary by Rupal J. Bhansali.

Check out latest stock trades

Top Ranked Articles about Johnson & Johnson

Investor Steven Romick's Top 5 Increases of First Quarter
FPA Crescent Fund’s Steven Romick (Trades, Portfolio) in the first quarter preferred to have cash ready to put to work in case volatility hit the markets, rather than buy new stocks. He believes a period of volatility – and the low-priced opportunities it would bring with it – could occur soon. Read more...
Gurus’ Most-Sold Fourth Quarter Stocks - Each at a 10-Year High
In the fourth quarter of 2013, the S&P 500 hit record highs, while the majority of corporations (95) reported negative EPS guidance, and 12 issued positive EPS guidance, according to FactSet Research. The estimated earnings growth rate for all corporations for the quarter was estimated to be 6.3%, according to FactSet. The Financial sector led growth, increasing earnings by 24.2%. Energy lagged all sectors, with an 8% decline in earnings. Read more...
Weekly 52-Week Highs Highlight: MAR, JNJ, HAL, BHI
According to GuruFocus list of 52-week highs; Marriott International Inc., Johnson & Johnson, Halliburton Company and Baker Hughes Inc. have all reached their 52-week highs. Read more...
Top Owned Health Care Stocks of the Fourth Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which health care companies are held by the most gurus. As of the fourth quarter, the following five health care companies are held by the largest number of gurus. Read more...
John Rogers' Ariel Fund Comments on Johnson & Johnson
Johnson & Johnson (JNJ) was a true favorite in the 1990s mega-cap bull market, with its glory days persisting until the end of 2002. From that point through 2010, it hit a relative rough patch. During the 1991 to 2002 period, Johnson & Johnson's revenues gained a remarkable +10.2% annually; in the subsequent period they slipped to a still-solid +6.8%. Its earnings decline was not as steep. The company compounded earnings per share (EPS) at a remarkable +13.6% in the 1990s and early 2000s period before slipping to +10.4% annually in the second era. Its price/earnings (P/E) ratios showcased its increasing popularity in the first period, as well as its fall from grace. Johnson & Johnson's earnings multiple soared from 26.1x in 1991 to a lofty 37.6x in 1998 before drifting down in the bear market to 24.9x at the end of 2002. From there it plummeted, however, to a low of just 12.9x at the end of 2010. Note that while investors chopped its P/E multiple in half from 2002 to 2010, its earnings per share more than doubled... Read more...
Money Managers Tweedy Browne Report New Stocks, Topped by Johnson & Johnson
Tweedy Browne (Trades, Portfolio) is a 93-year-old fund which focuses on undervalued securities, and which gained its investment approach from the late Benjamin Graham. The fund is owned and managed by William Browne, Thomas Shrager, John Spears and Robert Wyckoff, Jr. Read more...
Top Five Guru-Held Health Care Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which health care companies are held by the most gurus. As of the third quarter, the following five health care companies are held by the largest number of gurus. Read more...
Law of Diminishing Returns - Warren Buffett's Advised Experiment
Warren Buffett gave the following example as a law of diminishing returns and future revenue growth, and I decided to take him up on it: Read more...
Tweedy Browne – Third Quarter Stock Buy
Founded over 90 years ago, Tweedy Browne is a $19 billion investment firm still following in the steps of Benjamin Graham. Their funds returned a solid 5.3% and 8.47% for the third quarter, but the stock market’s continued climb reduced the number of undervalued opportunities. As the firm’s managers write in their third quarter letter: Read more...
Top Five Guru-Held Health Care Companies
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which healthcare companies are held by the most gurus. As of the second quarter, the following five health care companies are held by the largest number of gurus. [b] Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.50
JNJ's P/E(ttm) is ranked higher than
76% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.60 vs. JNJ: 20.50 )
JNJ' s 10-Year P/E(ttm) Range
Min: 10.5   Max: 25.71
Current: 20.5

10.5
25.71
P/B 3.70
JNJ's P/B is ranked higher than
55% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. JNJ: 3.70 )
JNJ' s 10-Year P/B Range
Min: 2.68   Max: 6.62
Current: 3.7

2.68
6.62
P/S 4.00
JNJ's P/S is ranked lower than
59% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. JNJ: 4.00 )
JNJ' s 10-Year P/S Range
Min: 2.16   Max: 4.28
Current: 4

2.16
4.28
PFCF 20.60
JNJ's PFCF is ranked higher than
75% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.79 vs. JNJ: 20.60 )
JNJ' s 10-Year PFCF Range
Min: 10.29   Max: 26.69
Current: 20.6

10.29
26.69
EV-to-EBIT 14.50
JNJ's EV-to-EBIT is ranked higher than
74% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. JNJ: 14.50 )
JNJ' s 10-Year EV-to-EBIT Range
Min: 8.4   Max: 18.7
Current: 14.5

8.4
18.7
PEG 9.20
JNJ's PEG is ranked lower than
51% of the 309 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. JNJ: 9.20 )
JNJ' s 10-Year PEG Range
Min: 1.18   Max: 246
Current: 9.2

1.18
246
Shiller P/E 21.80
JNJ's Shiller P/E is ranked higher than
71% of the 363 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.59 vs. JNJ: 21.80 )
JNJ' s 10-Year Shiller P/E Range
Min: 13.11   Max: 31.47
Current: 21.8

13.11
31.47

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.70
JNJ's Dividend Yield is ranked higher than
83% of the 418 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.38 vs. JNJ: 2.70 )
JNJ' s 10-Year Dividend Yield Range
Min: 1.57   Max: 3.84
Current: 2.7

1.57
3.84
Dividend Payout 0.54
JNJ's Dividend Payout is ranked lower than
57% of the 376 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. JNJ: 0.54 )
JNJ' s 10-Year Dividend Payout Range
Min: 0.34   Max: 0.65
Current: 0.54

0.34
0.65
Dividend growth (3y) 7.10
JNJ's Dividend growth (3y) is ranked higher than
81% of the 235 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. JNJ: 7.10 )
JNJ' s 10-Year Dividend growth (3y) Range
Min: 7.1   Max: 17.1
Current: 7.1

7.1
17.1
Yield on cost (5-Year) 3.86
JNJ's Yield on cost (5-Year) is ranked higher than
86% of the 429 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. JNJ: 3.86 )
JNJ' s 10-Year Yield on cost (5-Year) Range
Min: 2.24   Max: 5.49
Current: 3.86

2.24
5.49
Share Buyback Rate -1.00
JNJ's Share Buyback Rate is ranked higher than
79% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.70 vs. JNJ: -1.00 )
JNJ' s 10-Year Share Buyback Rate Range
Min: 2   Max: -4.9
Current: -1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 12.00
JNJ's Price/Tangible Book is ranked lower than
76% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. JNJ: 12.00 )
JNJ' s 10-Year Price/Tangible Book Range
Min: 6.74   Max: 17.99
Current: 12

6.74
17.99
Price/DCF (Projected) 1.60
JNJ's Price/DCF (Projected) is ranked higher than
71% of the 349 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. JNJ: 1.60 )
JNJ' s 10-Year Price/DCF (Projected) Range
Min: 0.97   Max: 3.6
Current: 1.6

0.97
3.6
Price/Median PS Value 1.20
JNJ's Price/Median PS Value is ranked higher than
58% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. JNJ: 1.20 )
JNJ' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.76
Current: 1.2

0.7
1.76
Price/Graham Number 3.30
JNJ's Price/Graham Number is ranked lower than
56% of the 470 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.20 vs. JNJ: 3.30 )
JNJ' s 10-Year Price/Graham Number Range
Min: 1.98   Max: 5.58
Current: 3.3

1.98
5.58
Earnings Yield (Greenblatt) 6.90
JNJ's Earnings Yield (Greenblatt) is ranked higher than
78% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. JNJ: 6.90 )
JNJ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.3   Max: 11.9
Current: 6.9

5.3
11.9
Forward Rate of Return (Yacktman) 1.01
JNJ's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. JNJ: 1.01 )
JNJ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1   Max: 18.2
Current: 1.01

1
18.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, PFE, RHHBY, NVS, ABT » details
Traded in other countries:JNJ.Germany
Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. It is a holding company, which has more than 250 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women"s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE a biologic approved for the treatment of Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT biotechnology-derived product that stimulates red blood cell production; RISPERDAL oral a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients. RISPERDAL CONSTA, a long-acting injectable, and INVEGATM Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN and FLOXIN, both in the anti-infective field; CONCERTA, a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal a treatment for chronic pain that offers a novel delivery system. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used mainly in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. In a

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Gurufocus
ReplyGurufocus - 6 months ago
test

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide